Pulmonary Artery Involvement in Takayasu's Arteritis

Pulmonary Artery Involvement in Takayasu's Arteritis: a Retrospective Study in China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03189602

Enrollment

Registered

2017-06-16

Start date

2014-01-01

Completion date

2015-12-31

Last updated

2017-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Artery Hypertension, Takayasu Arteritis

Keywords

Takayasu Arteritis, Pulmonary artery hypertension

Brief summary

The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of PA involvement in TA patients.

Detailed description

Takayasu's arteritis patients with pulmonary artery involvement were enrolled into this study. The demographic information of the patients (age, sex, course of disease), symptoms at their admissions (cough, hemoptysis, dyspnea, palpitations, fever), laboratory examinations (blood lab routines, erythrocyte sedimentation rate, C-reactive protein), and imaging examinations (vascular ultrasonography, computed tomographic angiography, echocardiography, chest CT, CTPA, pulmonary perfusion imaging, pulmonary angiography, PET/CT) were collected by reviewing the cases. The prognostic information was collected by telephone follow-up. The follow-up end point was December 2015.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

14 Years to 67 Years

Healthy volunteers

Inclusion criteria

* 1.Meet the diagnostic criteria of TA as defined by the American College of Rheumatology (ACR). * 2.PA involvement: meet at least one of three items: (1) at least one of computed tomographic pulmonary angiography (CTPA), pulmonary perfusion imaging, or pulmonary arteriography suggests thickening of vessel wall, stenosis, aneurysm, or occlusion; (2) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) suggests high intake of local radioactive material in pulmonary artery wall; (3) pulmonary artery systolic blood pressure is higher than 50 mmHg assessed by transthoracic echocardiography (defined as PAH), without left ventricular disease.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Pulmonary Artery Systolic Blood Pressure	1day	Pulmonary artery systolic blood pressure(PASP) assessed by transthoracic echocardiography when admission. PASP\>50mmHg is defined as pulmonary hypertension.

Countries

China

Outcome results